Your cart is empty
Add prompt packs to continue
This collection of prompts represents the cutting edge in the design of artificial intelligence tools applied to clinical and forensic psychiatry. Meticulously designed by content strategy and medical experts, this library enables psychiatrists to automate the generation of complex technical documentation, from legal liability reports to detailed pharmacotherapy plans, ensuring terminological accuracy and medical rigor in seconds. By integrating these prompts into their workflow, the professional optimizes the interpretation of psychometric tests, the writing of hospital epicrises, and the monitoring of therapeutic plasma levels. It is the ultimate solution to reduce administrative burden, allowing the clinician to focus on critical decision-making and patient well-being, raising the standards of modern psychiatric practice through the strategic use of AI.
100 resources included
He acts as a psychiatrist expert in Dual Pathology and Addiction Medicine with extensive experience in highly complex hospital environments. Your task is to develop a detailed clinical intervention protocol for the in-hospital detoxification of a patient with severe alcohol use disorder and the following clinical variables: [Patient's age], [Major psychiatric comorbidity], [Years of consumption history], and [Relevant analytical/hepatic findings]. The protocol must begin with a thorough evaluation of the immediate risks. It uses and details the application of the CIWA-Ar scale (Clinical Institute Withdrawal Assessment for Alcohol) for symptom monitoring, establishing specific cut-off points for proactive pharmacological intervention. Describes the management of the Benzodiazepine regimen (such as Diazepam or Lorazepam) considering the patient's liver function [Liver status], specifying whether a fixed regimen with rescues or a regimen guided exclusively by symptoms will be chosen to minimize excessive sedation and the risk of respiratory failure. It compulsorily integrates a prophylaxis and treatment scheme for neurocognitive complications. Develops the Thiamine (Vitamin B1) administration regimen following international guidelines for the prevention of Wernicke-Korsakoff Syndrome, detailing dosage, route of administration (IV/IM/PO) and duration of treatment before glucose loading. It also includes the management of critical electrolyte alterations such as hypomagnesemia and hypokalemia, which are common in this patient profile and increase the risk of arrhythmias and seizures. In the context of Dual Pathology, it analyzes the management of pre-existing psychiatric medication for [Main psychiatric comorbidity]. Determines which drugs should be maintained, adjusted, or temporarily discontinued due to the risk of lowering the seizure threshold or interacting with detoxification treatment. It provides clear safety criteria for monitoring psychotic or affective symptoms that may be exacerbated during acute withdrawal, differentiating between withdrawal symptoms and decompensation of the underlying pathology. It concludes with a transition plan towards the cessation phase. Evaluates the suitability of starting anticraving drugs such as [Naltrexone / Acamprosate / Disulfiram / Baclofen] once the acute condition has been stabilized. Establishes hospital discharge criteria and recommendations for intensive outpatient follow-up in the addictive behavior unit, ensuring continuity of care that addresses both the addiction and the concomitant mental disorder.
He acts as a psychiatrist expert in adult neurodevelopment and a specialist in clinical psychometry. Your task is to carry out a comprehensive and detailed analysis of the screening results for Attention Deficit Hyperactivity Disorder (ADHD) in an adult patient, based on the data that I will provide you below: [ASRS v1.1 Scale Scores], [DIVA-5 Interview Results], [WURS Score for childhood retrospective] and [Current clinical symptoms described by the patient]. First, it evaluates the validity of the results of the Adult ADHD Self-Report Scale (ASRS v1.1). Analyzes whether the scores in Part A (the first 6 items) are predictive of a clinical diagnosis according to WHO thresholds, and cross-references this information with the findings of Part B to determine the frequency and chronicity of inattention and hyperactivity/impulsivity symptoms. It is essential that you establish whether the profile suggests a predominantly inattentive, hyperactive-impulsive or combined presentation, justifying each conclusion with the DSM-5-TR criteria. Secondly, it integrates the findings of the DIVA-5 interview and the WURS scale (Wender Utah Rating Scale). For a diagnosis of ADHD in adults, it is imperative to demonstrate that the symptoms were present before the age of 12. Analyzes whether the childhood data in [Childhood History] meet the threshold of clinical significance and how these have evolved into adulthood. Evaluate the current functional impact in at least two areas of the patient's life (work, academic, social, domestic) based on [Reported functional impact]. Finally, perform a differential diagnosis and comorbidity analysis. ADHD in adults often overlaps with mood disorders, anxiety, or personality disorders. Use the data from [Suspected comorbidities or overlapping symptoms] to rule out that symptoms of poor concentration or restlessness are better explained by a depressive episode, generalized anxiety disorder, or borderline personality disorder. It concludes with a clinical synthesis that recommends the next diagnostic steps or adjustments in the pharmacological and psychotherapeutic treatment plan.
He acts as a Senior Psychiatrist specialized in Dual Pathology and Addiction Medicine. Your mission is to develop an advanced pharmacological intervention protocol for the management of craving in a patient who simultaneously presents a Substance Use Disorder (SUD) and a concomitant psychiatric pathology. The clinical profile is as follows: [Age and Gender of the Patient], with a main diagnosis of dependence on [Substance: e.g. Alcohol, Cocaine, Opioids] in [Phase: e.g. Acute Detoxification, Abstinence Maintenance] and a comorbidity of [Mental Disorder: e.g. Borderline Personality Disorder, Schizophrenia, Bipolar Disorder]. It begins by performing a detailed neurobiological analysis of the brain circuits involved in the patient's craving, considering both the dopaminergic reward system and the deregulation of the glutamatergic and GABAergic systems specific for the aforementioned substance. Explains how dual pathology [Mental Disorder] exacerbates vulnerability to craving and makes impulse control difficult in this particular case. Propose a multicomponent pharmacological scheme. It includes: 1) First-line anticraving drugs (e.g. Naltrexone, Acamprosate, Buprenorphine or Varenicline) with pharmacodynamic justification. 2) Adjuvant or second-line drugs (e.g. Topiramate, Gabapentin, Baclofen) to control impulsivity and anticipatory anxiety. 3) Necessary adjustments in the background medication for the mental disorder ([Patient's Current Medication]) to avoid pharmacokinetic interactions through cytochrome P450 or dangerous sedative synergies. Design a clinical monitoring plan that includes the use of validated scales to quantify craving (e.g. Visual Analog Scale - VAS, OCDS or PACS) and clear criteria for escalating or de-escalating the dose. It also establishes a 'rescue medication' protocol for intense craving crises, detailing drugs, maximum doses and warnings about the risk of addiction substitution. It concludes with recommendations on the integration of this pharmacological management with high-intensity psychotherapeutic interventions such as Mindfulness-based Relapse Prevention or Acceptance and Commitment Therapy.